Phase II trial of capecitabine combined with thalidomide in second-line treatment of advanced pancreatic cancer

Pancreatology

Volumn 12, Issue 6, 2012, Pages 475-479

  Shi, Sheng Bin ^a   Wang, Meng ^b   Niu, Zuo Xing ^a   Tang, Xiao Yong ^a   Liu, Quan Yun ^a  

^a LINYI PEOPLE'S HOSPITAL   (China)

^b Shang Dong Ji Ning First People's Hospital   (China)

Author keywords

Capecitabine; Pancreatic cancer; Second line; Thalidomide

Indexed keywords

CA 19-9 ANTIGEN; CAPECITABINE; CAPECITABINE PLUS OXALIPLATIN; CELECOXIB; FLUOROURACIL; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PEMETREXED; SELUMETINIB; THALIDOMIDE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DISEASE COURSE; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; MALE; NAUSEA AND VOMITING; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RASH; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84873844378     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1016/j.pan.2012.09.007     Document Type: Article

References (25)

1. American Cancer Society. Cancer facts & figures 2009; 2010. Available from: http://www.cancer.org/acs/groups/content/@nho/documents/document/ 500809webpdf.pdf [accessed October 2010].
2. Saif MW. Controversies in the adjuvant treatment of pancreatic adenocarcinoma. Journal of Pancreas (Online) 2007;8(5):545-52.
3. Burris III HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. Journal of Clinical Oncology 1997;15:2403-13.
4. Correale P, Messinese S, Marsili S, Ceciarini F, Pozzessere D, et al. A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5- fluorouracil and folinic acid. British Journal of Cancer 2003 Jul 21;89(2): 239-42.
5. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. Journal of Clinical Oncology 2005;23:3509-16.
6. NCCN Practice Guidelines in Oncology™, Pancreatic adenocarcinoma (version 2. 2010); 2010. Available from: http://www.nccn.org/professionals/ physician-gls/f-guidelinesasp [accessed October 2010].
7. Cartwright TH, Cohn A, Varkey JA, Chen YM, Szatrowski TP, Cox JV, et al. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. Journal of Clinical Oncology 2002;20:160-4.
8. Boeck S, Wilkowski R, Bruns CJ, Issels RD, Schulz C, et al. Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer. Oncology 2007;73:221-7.
9. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nature Reviews Cancer 2004;4(4):314-22.
10. Gordon JN, Trebble TM, Ellis RD, Duncan HD, Johns T, et al. Thalidomide in the treatment of cancer cachexia:a randomized placebo controlled trial. Gut 2005 Apr;54(4):540-5.
11. Du GJ, Lin HH, Xu QT, Wang MW. Thalidomide inhibits growth of tumors through COX-2 degradation independent of antiangiogenesis. Vascul Pharmacol 2005;43(2):112-9.
12. Nakachi K, Furuse J, Ishii H, Suzuki E, Yoshino M. Prognostic factors in patients with gemcitabine-refractory pancreatic cancer. Japanese Journal of Clinical Oncology 2007;37(2):114-20.
13. Hada M, Mizutari K. A case report of metastatic pancreatic cancer that responded remarkably to the combination of thalidomide, celecoxib and irinotecan. Gan To Kagaku Ryoho 2004;31:1407-10.
14. Hada M, Mizutari K. A case of advanced pancreatic cancer with remarkable response to thalidomide, celecoxib and gemcitabine. Gan To Kagaku Ryoho 2004;31:959-61.
15. Yoo C, Hwang JY, Kim JE, Kim TW, Lee JS, Park DH, et al. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. British Journal of Cancer 2009;101(10):1658-63.
16. Blaya M, Lopes Jr GL, Roman E, Ahn E, Macintyre J, Quesada J, et al. Phase II trial of capecitabine and docetaxel as second line therapy for locally advanced and metastatic pancreatic cancer. 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Journal of Clinical Oncology 2007;25(18S (June 20 Suppl.)):15029.
17. Novarino A, Satolli MA, Chiappino I. Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer. American Journal of Clinical Oncology 2009;32(1):44-8.
18. NCCN Clinical Practice Guidelines in Oncology. Pancreatic adenocarcinoma, vol. 1. NCCN, http://www.nccn.org/professionals/physician-gls/PDF/pancreatic. pdf; 2008.
19. Saif MW. New developments in the treatment of pancreatic cancer. Highlights from the "44th ASCO annual meeting", Chicago, IL, USA. Journal of Pancreas May 30eJune 3, 2008;9(4):391-7.
20. Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, et al. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 2008;113(8):2046-52.
21. Bodoky G, Timcheva C, Spigel DR, La Stella PJ, Ciuleanu TE, et al. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Investigational New Drugs 2011 May 19.
22. Pino MS, Milella M, Gelibter A, Sperduti I, De Marco S, et al. Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. Oncology 2009;76(4):254-61.
23. Lozano-Leon A, Perez-Quintela BV, Iglesias-García J, Urisarri-Ruiz A, Lariño- Noia J, et al. Clinical relevance of epidermal growth factor receptor (EGFR) alterations in human pancreatic tumors. Oncology Reports 2011;26(2):315-20.
24. Varker KA, Campbell J, Shah MH. Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors. Cancer Chemotheraphy and Pharmacology 2008;61(4):661-8.
25. Shan YS, Lin PW. A phase I study of combination of intravenous gemcitabine, oxaliplatin, and 5-FU with daily oral thalidomide (GOFT) in metastatic/locally advanced pancreatic carcinoma patients. Hepatogastroenterology 2007; 54(79):2141-5.